Compare Amgen, Inc. (AMGN) vs Xcel Energy Inc (XEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Xcel Energy Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Xcel Energy Inc trades at $80.06 (market cap $49.98B). The key difference: Amgen, Inc. is far larger — about 3.9× Xcel Energy Inc's market cap, and Xcel Energy Inc pays the higher dividend (2.96%). Which is the better fit depends on your goals.
| AMGN | XEL | |
|---|---|---|
Market Cap | $196.12B | $49.98B |
Sector | Health | Utilities |
52-Week High | $388.16 | $83.91 |
52-Week Low | $271.18 | $68.33 |
Enterprise Value | $241.41B | $87.42B |
Dividend Yield | 2.77% | 2.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
XEL trades at $80.06, up 1.32% today, with a bearish technical signal but strong analyst consensus. Recent earnings showed a Q1 2026 beat but two prior misses. The company maintains solid fundamentals with $14.67B revenue, 14.14% net margin, and a $60B capital plan driving growth. Dividend yield is 2.87% with a recent $0.59 payout declared.
Outlook is positive with Wall Street's $91.88 price target suggesting 15% upside, supported by data center demand and infrastructure investments. Risks include regulatory pushback on rate hikes and high debt levels. The stock presents a steady utility play with growth catalysts but requires monitoring of earnings consistency and capex execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
